Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Case Medical Research

• Publication date

  2019-05-06

• Fields of study

  Not labeled

• Identifiers
  DOI 10.31525/ct1-nct03937830
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.

  2020cites this paper